- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Brigatinib Maintains Long-Term Efficacy in Crizotinib-Refractory ALK+ NSCLC
June 4th 2021, 4:47pm
Brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.
Extended Treatment With Darolutamide Well Tolerated, Prolongs Survival in Nonmetastatic CRPC
June 4th 2021, 4:41pm
Darolutamide remained well tolerated with a highly favorable safety profile when combined with androgen deprivation therapy in the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Pralsetinib Is Tolerable, Durable in RET Fusion-Positive NSCLC
June 4th 2021, 4:40pm
Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.
Higher Dose of Ripretinib Improves Outcomes in Heavily Pretreated Advanced GIST
June 4th 2021, 4:37pm
Intra-patient dose escalation of ripretinib to 150 mg twice a day following disease progression extended progression-free survival for patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy.
Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
June 4th 2021, 4:30pm
The CAR T-cell therapy idecabtagene vicleucel continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.
PFS Improved With Niraparib Maintenance in BRCA+ Ovarian Cancer
June 4th 2021, 4:21pm
Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.
Lenvatinib Plus Pembrolizumab May Increase OS Rates in Advanced Colorectal Cancer
June 4th 2021, 3:44pm
Some patients with previously treated advanced colorectal cancer responded to treatment with lenvatinib plus pembrolizumab.
Frontline Nivolumab Plus Ipilimumab or Chemo Improves Survival Outcomes in Advanced ESCC
June 3rd 2021, 9:00pm
The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.
Adjuvant Pembrolizumab Significantly Improves DFS in Renal Cell Carcinoma
June 3rd 2021, 9:00pm
Pembrolizumab was associated with a 32% reduction in the risk of disease recurrence or death compared with placebo as an adjuvant treatment for patients with clear cell renal cell carcinoma.
Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer
June 3rd 2021, 9:00pm
Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence.
Adjuvant Chemotherapy Fails to Improve PFS and OS in Locally Advanced Cervical Cancer
June 3rd 2021, 9:00pm
The administration of adjuvant carboplatin and paclitaxel following standard cisplatin-based chemoradiation failed to demonstrate an improvement in progression-free survival or overall survival in women with locally advanced cervical cancer, according to findings from the phase 3 OUTBACK trial.
Frontline Toripalimab Plus Gemcitabine/Cisplatin Significantly Improves PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma
June 3rd 2021, 9:00pm
The addition of the immunotherapy agent toripalimab to gemcitabine plus cisplatin demonstrated superior progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to data from the phase 3 JUPITER-02 trial.
Cancer Experts Preview Pivotal Trials at ASCO 2021
May 28th 2021, 7:00pm
Experts in breast cancer, gynecologic malignancies, lung cancer, multiple myeloma, gastrointestinal cancers, and genitourinary cancers shared their perspectives on the biggest abstracts being presented at the 2021 ASCO Annual Meeting.
States With Lower Medicaid Eligibility Limits May Have Worse Survival Rates Among Patients with Cancer
May 19th 2021, 9:01pm
Patients with cancer who live in states with lower Medicaid income eligibility limits had worse long-term survival outcomes compared with those with higher eligibility limits.
Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma
May 19th 2021, 9:00pm
The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.
Adjuvant Atezolizumab Significantly Improves DFS in Early-Stage NSCLC
May 19th 2021, 9:00pm
Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival vs best supportive care in patients with stage II to IIIA non–small cell lung cancer, particularly those with PD-L1–positive tumors, according to findings from the phase 3 IMpower010 trial.
Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans
May 19th 2021, 9:00pm
An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.
Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer
May 18th 2021, 10:43pm
Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
Dr. Doroshow on the Importance of Modernizing Clinical Trials After COVID-19
May 18th 2021, 9:24pm
James H. Doroshow, MD, discusses the importance of modernizing clinical trials in the post–COVID-19 era.
Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era
May 18th 2021, 6:20pm
Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.